(E)-N-[3-[6-amino-8-[[6-(1,3-thiazol-2-yl)-1,3-benzodioxol-5-yl]sulfanyl]purin-9-yl]propyl]-2-cyano-3-[6-(4-methylpiperazin-1-yl)naphthalen-2-yl]prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (E)-N-[3-[6-amino-8-[[6-(1,3-thiazol-2-yl)-1,3-benzodioxol-5-yl]sulfanyl]purin-9-yl]propyl]-2-cyano-3-[6-(4-methylpiperazin-1-yl)naphthalen-2-yl]prop-2-enamide
• 化学式: C₃₇H₃₄N₁₀O₃S₂
• 分子量: 730.9
• InChiKey: IUIXUHJXLNSCBV-WGOQTCKBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  52
• 可旋转键数：
  10
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  214
• 氢给体数：
  2
• 氢受体数：
  13

文献信息

• USES OF LABELED HSP90 INHIBITORS
  申请人：Chiosis Gabriela

  公开号：US20140242602A1

  公开（公告）日：2014-08-28

  The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6).
• US9555137B2
  申请人：——

  公开号：US9555137B2

  公开（公告）日：2017-01-31